JP2017517506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517506A5 JP2017517506A5 JP2016568497A JP2016568497A JP2017517506A5 JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5 JP 2016568497 A JP2016568497 A JP 2016568497A JP 2016568497 A JP2016568497 A JP 2016568497A JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- heavy chain
- light chain
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 239000000556 agonist Substances 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 102000009410 Chemokine receptor Human genes 0.000 claims 3
- 108050000299 Chemokine receptor Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000037844 advanced solid tumor Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000037843 metastatic solid tumor Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001534P | 2014-05-21 | 2014-05-21 | |
| US62/001,534 | 2014-05-21 | ||
| PCT/US2015/031081 WO2015179236A1 (en) | 2014-05-21 | 2015-05-15 | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517506A JP2017517506A (ja) | 2017-06-29 |
| JP2017517506A5 true JP2017517506A5 (cg-RX-API-DMAC10.html) | 2018-07-12 |
Family
ID=53284562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568497A Pending JP2017517506A (ja) | 2014-05-21 | 2015-05-15 | 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用 |
Country Status (12)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2937035A1 (en) * | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| KR20180103150A (ko) * | 2016-01-25 | 2018-09-18 | 화이자 인코포레이티드 | 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합 |
| EP3471754A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 antibodies |
| AU2017363337B2 (en) * | 2016-11-23 | 2021-07-01 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| CA3039772C (en) | 2017-01-06 | 2020-08-25 | Eutilex Co., Ltd. | Anti-human 4-1bb antibodies and uses thereof |
| KR102144658B1 (ko) * | 2017-03-29 | 2020-08-14 | 시오노기세이야쿠가부시키가이샤 | 암 치료용 의약 조성물 |
| EP4461825A3 (en) | 2017-06-09 | 2024-11-20 | Providence Health & Services - Oregon | Tumor-infiltrating t-cells for use in the treatment of cancer |
| JP7402521B2 (ja) | 2017-07-11 | 2023-12-21 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用 |
| WO2019072274A1 (zh) * | 2017-10-12 | 2019-04-18 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| CN109651507B (zh) | 2017-10-12 | 2021-11-26 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| SG11202004105TA (en) | 2017-11-06 | 2020-06-29 | Rapt Therapeutics Inc | Anticancer agents |
| WO2019100052A2 (en) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019109238A1 (en) | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| RU2020127196A (ru) * | 2018-01-22 | 2022-02-24 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение |
| KR102836393B1 (ko) * | 2018-03-13 | 2025-07-22 | 에프. 호프만-라 로슈 아게 | 4-1bb 작용제와 항-cd20 항체의 치료 조합 |
| WO2019196868A1 (en) * | 2018-04-10 | 2019-10-17 | Wuxi Biologics (Shanghai) Co., Ltd. | A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof |
| CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CA3107019A1 (en) | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy |
| AU2020263959B2 (en) | 2019-04-24 | 2026-01-22 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| EP3966252A4 (en) | 2019-05-10 | 2023-01-25 | Lyvgen Biopharma Holdings Limited | HUMANIZED ANTI-CD137 ANTIBODIES AND THEIR USES |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| MX2022008632A (es) * | 2020-01-13 | 2022-08-08 | Cytodyn Inc | Agente de union a ccr5 para el tratamiento de cancer metastasico positivo para ccr5. |
| KR20220137054A (ko) * | 2020-02-04 | 2022-10-11 | 젠맵 에이/에스 | 요법에 사용하기 위한 항체 |
| EP4103285A2 (en) * | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
| EP4228627A4 (en) * | 2020-10-13 | 2024-11-06 | Board of Regents, The University of Texas System | COMBINATORIAL IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PANCREATIC DUCT ADENOCARCINOMA |
| AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| KR20240049794A (ko) | 2021-06-07 | 2024-04-17 | 프로비던스 헬스 앤드 서비시즈 - 오레곤 | Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도 |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| TW202309097A (zh) | 2021-07-14 | 2023-03-01 | 美商建南德克公司 | 抗ｃ－ｃ模體趨化因子受體８（ｃｃｒ８）抗體及其使用方法 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CN1214043C (zh) | 1998-12-01 | 2005-08-10 | 蛋白质设计实验室股份有限公司 | 抗γ－干扰素的人化抗体 |
| CN1296960A (zh) * | 1999-11-22 | 2001-05-30 | 上海博容基因开发有限公司 | 一种新的多肽——人ccr4相关蛋白31和编码这种多肽的多核苷酸 |
| MXPA04001894A (es) | 2001-08-31 | 2005-09-08 | Kyowa Hakko Kogyo Kk | Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo. |
| CN1688603A (zh) * | 2002-07-15 | 2005-10-26 | 马约医学教育与研究基金会 | 使用4－1bb结合剂的治疗和预防 |
| JPWO2005053741A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬 |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| EP1827487A2 (en) | 2004-11-17 | 2007-09-05 | Board of Regents, The University of Texas System | Cancer immunotherapy incorporating p53 |
| EP1851244A4 (en) * | 2005-02-15 | 2009-04-15 | Gtc Biotherapeutics Inc | ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF |
| US20080194596A1 (en) | 2005-06-03 | 2008-08-14 | Frizer Inc. | Therapeutic Combination Including a Selective Erbb2 Inhibitor |
| US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| CA2810359C (en) | 2010-09-09 | 2021-06-22 | Pfizer Inc. | 4-1bb binding molecules |
| TWI589587B (zh) | 2010-11-19 | 2017-07-01 | 衛材Ｒ＆Ｄ企管股份有限公司 | 中和性抗－ｃｃｌ２０抗體 |
-
2015
- 2015-05-15 WO PCT/US2015/031081 patent/WO2015179236A1/en not_active Ceased
- 2015-05-15 EP EP15727159.4A patent/EP3145956A1/en not_active Withdrawn
- 2015-05-15 BR BR112016026993A patent/BR112016026993A2/pt not_active Application Discontinuation
- 2015-05-15 KR KR1020167035347A patent/KR20170004006A/ko not_active Withdrawn
- 2015-05-15 CN CN201580027437.7A patent/CN106413751A/zh active Pending
- 2015-05-15 JP JP2016568497A patent/JP2017517506A/ja active Pending
- 2015-05-15 AU AU2015264528A patent/AU2015264528A1/en not_active Abandoned
- 2015-05-15 US US15/312,515 patent/US10023649B2/en not_active Expired - Fee Related
- 2015-05-15 RU RU2016146993A patent/RU2016146993A/ru not_active Application Discontinuation
- 2015-05-15 CA CA2949214A patent/CA2949214A1/en not_active Abandoned
- 2015-05-15 MX MX2016015181A patent/MX2016015181A/es unknown
-
2016
- 2016-10-27 IL IL248540A patent/IL248540A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017517506A5 (cg-RX-API-DMAC10.html) | ||
| Suurs et al. | A review of bispecific antibodies and antibody constructs in oncology and clinical challenges | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| JP2017516775A5 (cg-RX-API-DMAC10.html) | ||
| MX2024015039A (es) | Composiciones anti-cd24 y usos de las mismas | |
| JP2016041733A5 (cg-RX-API-DMAC10.html) | ||
| JP2017510661A5 (cg-RX-API-DMAC10.html) | ||
| BRPI0918178A8 (pt) | anticorpos monoclonais para tratamento de câncer | |
| JP2015214582A5 (cg-RX-API-DMAC10.html) | ||
| JP2017505782A5 (cg-RX-API-DMAC10.html) | ||
| JP2019506403A5 (cg-RX-API-DMAC10.html) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| WO2017097723A3 (en) | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies | |
| JP2015534578A5 (cg-RX-API-DMAC10.html) | ||
| JP2015500225A5 (cg-RX-API-DMAC10.html) | ||
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| JP2016510028A5 (cg-RX-API-DMAC10.html) | ||
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| NZ724368A (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| Lin et al. | Combination treatment including targeted therapy for advanced hepatocellular carcinoma | |
| JP2009505676A5 (cg-RX-API-DMAC10.html) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| MX2016008362A (es) | Combinaciones farmaceuticas. |